Proteomic Profiling of Dilated Cardiomyopathy Plasma Samples  Searching for Biomarkers with Potential to Predict the Outcome of Therapy

Determination of the prognosis and treatment outcomes
of dilated
cardiomyopathy is a serious problem due to the lack of valid specific
protein markers. Using in-depth proteome discovery analysis, we compared
49 plasma samples from patients suffering from dilated cardiomyopathy
with plasma samples from their healthy counterparts. In total, we
identified 97 proteins exhibiting statistically significant dysregulation
in diseased plasma samples. The functional enrichment analysis of
differentially expressed proteins uncovered dysregulation in biological
processes like inflammatory response, wound healing, complement cascade,
blood coagulation, and lipid metabolism in dilated cardiomyopathy
patients. The same proteome approach was employed in order to find
protein markers whose expression differs between the patients well-responding
to therapy and nonresponders. In this case, 45 plasma proteins revealed
statistically significant different expression between these two groups.
Of them, fructose-1,6-bisphosphate aldolase seems to be a promising
biomarker candidate because it accumulates in plasma samples obtained
from patients with insufficient treatment response and with worse
or fatal outcome. Data are available via ProteomeXchange with the
identifier PXD046288.